Kunwei Li

Shuaitong Zhang, Yuchen Sun, Yong Ao et al.

Longitudinal medical images are essential for monitoring disease progression by capturing spatiotemporal changes associated with dynamic biological processes. While current methods have made progress in modeling spatiotemporal patterns, they face three key limitations: (1) lack of generalizable framework applicable to diverse disease progression prediction tasks; (2) frequent overlook of the ordinal nature inherent in disease staging; (3) susceptibility to representation collapse due to structural similarities between adjacent time points, which can obscure subtle but discriminative progression biomarkers. To address these limitations, we propose a Generalizable LOngitudinal Medical Image Analysis framework for disease Progression prediction (GLOMIA-Pro). GLOMIA-Pro consists of two core components: progression representation extraction and progression-aware fusion. The progression representation extraction module introduces a piecewise orthogonal attention mechanism and employs a novel ordinal progression constraint to disentangle finegrained temporal imaging variations relevant to disease progression. The progression-aware fusion module incorporates a redesigned skip connection architecture which integrates the learned progression representation with current imaging representation, effectively mitigating representation collapse during cross-temporal fusion. Validated on two distinct clinical applications: knee osteoarthritis severity prediction and esophageal cancer treatment response assessment, GLOMIA-Pro consistently outperforms seven state-of-the-art longitudinal analysis methods. Ablation studies further confirm the contribution of individual components, demonstrating the robustness and generalizability of GLOMIA-Pro across diverse clinical scenarios.

Han Wu, Wenjie Ruan, Jiangtao Wang et al.

The black-box nature of machine learning models hinders the deployment of some high-accuracy models in medical diagnosis. It is risky to put one's life in the hands of models that medical researchers do not fully understand. However, through model interpretation, black-box models can promptly reveal significant biomarkers that medical practitioners may have overlooked due to the surge of infected patients in the COVID-19 pandemic. This research leverages a database of 92 patients with confirmed SARS-CoV-2 laboratory tests between 18th Jan. 2020 and 5th Mar. 2020, in Zhuhai, China, to identify biomarkers indicative of severity prediction. Through the interpretation of four machine learning models, decision tree, random forests, gradient boosted trees, and neural networks using permutation feature importance, Partial Dependence Plot (PDP), Individual Conditional Expectation (ICE), Accumulated Local Effects (ALE), Local Interpretable Model-agnostic Explanations (LIME), and Shapley Additive Explanation (SHAP), we identify an increase in N-Terminal pro-Brain Natriuretic Peptide (NTproBNP), C-Reaction Protein (CRP), and lactic dehydrogenase (LDH), a decrease in lymphocyte (LYM) is associated with severe infection and an increased risk of death, which is consistent with recent medical research on COVID-19 and other research using dedicated models. We further validate our methods on a large open dataset with 5644 confirmed patients from the Hospital Israelita Albert Einstein, at São Paulo, Brazil from Kaggle, and unveil leukocytes, eosinophils, and platelets as three indicative biomarkers for COVID-19.